Literature DB >> 21713550

CD44+/CD24- cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast.

Daniel Guimarães Tiezzi1, Fernando Antonio Mourão Valejo, Heitor Ricardo Cosinski Marana, Hélio Humberto Angotti Carrara, Luciana Benevides, Heriton Marcelo Ribeiro Antonio, Renata Danielle Sicchieri, Cristiane Maria Milanezi, João Santana da Silva, Jurandyr Moreira de Andrade.   

Abstract

The presence of tumor-initiating cells (CD44(+)/CD24(-)) in solid tumors has been reported as a possible cause of cancer metastasis and treatment failure. Nevertheless, little is know about the presence of CD44(+)/CD24(-) cells within the primary tumor and metastasis. The proportion of CD44(+)/CD24(-) cells was analyzed in 40 samples and in 10 lymph node metastases using flow cytometry phenotyping. Anti-human CD326 (EpCam; FITC), anti-human CD227 (MUC-1; FITC), anti-human CD44 (APC), and anti-human CD24 (PE), anti-ABCG2 (PE), and anti-CXCR4 (PeCy7) were used for phenotype analysis. The mean patient age was 60.5 years (range, 33-87 years); mean primary tumor size (pT) was 1.8 cm (0.5-3.5 cm). The Wilcoxon or Kruskal-Wallis test was used for univariate analyses. Logistic regression was used for multivariate analysis. The median percentage of CD44(+)/CD24(-) cells within primary invasive ductal carcinomas (IDC) was 2.7% (range, 0.2-71.2). In lymph node metastases, we observed a mean of 6.1% (range, 0.07-53.7). The percentage of CD44(+)/CD24(-) cells in IDCs was not associated with age, pT, tumor grade and HER2. We observed a significantly enrichment of CD44(+)/CD24(-) and ABCG2(+) cells in ESA(+) cell population in patients with positive lymph nodes (P = 0.02 and P = 0.04, respectively). Our data suggest that metastatic dissemination is associated with an increase in tumor-initiating cells in stage I and II breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21713550     DOI: 10.1007/s12032-011-0014-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  Hypoxia signalling in cancer and approaches to enforce tumour regression.

Authors:  Jacques Pouysségur; Frédéric Dayan; Nathalie M Mazure
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays.

Authors:  Patrick L Fitzgibbons; Douglas A Murphy; M Elizabeth H Hammond; D Craig Allred; Paul N Valenstein
Journal:  Arch Pathol Lab Med       Date:  2010-06       Impact factor: 5.534

3.  A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma.

Authors:  H Geminder; O Sagi-Assif; L Goldberg; T Meshel; G Rechavi; I P Witz; A Ben-Baruch
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

6.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Authors:  Benny K Abraham; Peter Fritz; Monika McClellan; Petra Hauptvogel; Maria Athelogou; Hiltrud Brauch
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

7.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

8.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

9.  The molecular portraits of breast tumors are conserved across microarray platforms.

Authors:  Zhiyuan Hu; Cheng Fan; Daniel S Oh; J S Marron; Xiaping He; Bahjat F Qaqish; Chad Livasy; Lisa A Carey; Evangeline Reynolds; Lynn Dressler; Andrew Nobel; Joel Parker; Matthew G Ewend; Lynda R Sawyer; Junyuan Wu; Yudong Liu; Rita Nanda; Maria Tretiakova; Alejandra Ruiz Orrico; Donna Dreher; Juan P Palazzo; Laurent Perreard; Edward Nelson; Mary Mone; Heidi Hansen; Michael Mullins; John F Quackenbush; Matthew J Ellis; Olufunmilayo I Olopade; Philip S Bernard; Charles M Perou
Journal:  BMC Genomics       Date:  2006-04-27       Impact factor: 3.969

10.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Authors:  Gabriella Honeth; Pär-Ola Bendahl; Markus Ringnér; Lao H Saal; Sofia K Gruvberger-Saal; Kristina Lövgren; Dorthe Grabau; Mårten Fernö; Ake Borg; Cecilia Hegardt
Journal:  Breast Cancer Res       Date:  2008-06-17       Impact factor: 6.466

View more
  10 in total

1.  Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Authors:  Thanh U Barbie; Gabriela Alexe; Amir R Aref; Shunqiang Li; Zehua Zhu; Xiuli Zhang; Yu Imamura; Tran C Thai; Ying Huang; Michaela Bowden; John Herndon; Travis J Cohoon; Timothy Fleming; Pablo Tamayo; Jill P Mesirov; Shuji Ogino; Kwok-Kin Wong; Matthew J Ellis; William C Hahn; David A Barbie; William E Gillanders
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival.

Authors:  Erhong Meng; Beverely Long; Paula Sullivan; Steve McClellan; Michael A Finan; Eddie Reed; Lalita Shevde; Rodney P Rocconi
Journal:  Clin Exp Metastasis       Date:  2012-05-18       Impact factor: 5.150

3.  Nanog siRNA plus Cisplatin may enhance the sensitivity of chemotherapy in esophageal cancer.

Authors:  Yaming Du; Leizhi Shi; Tianyi Wang; Zhiliang Liu; Zhongbin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-20       Impact factor: 4.553

4.  ABCG2 is a potential marker of tumor-initiating cells in breast cancer.

Authors:  Renata Danielle Sicchieri; Willian Abraham da Silveira; Larissa Raquel Mouro Mandarano; Tatiane Mendes Gonçalves de Oliveira; Hélio Humberto Angotti Carrara; Valdair Francisco Muglia; Jurandyr Moreira de Andrade; Daniel Guimarães Tiezzi
Journal:  Tumour Biol       Date:  2015-06-20

5.  Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment.

Authors:  Phuc Van Pham; Ngoc Bich Vu; Thuy Thanh Duong; Tam Thanh Nguyen; Nhung Hai Truong; Nhan Lu Chinh Phan; Tue Gia Vuong; Viet Quoc Pham; Hoang Minh Nguyen; Kha The Nguyen; Nhung Thi Nguyen; Khue Gia Nguyen; Lam Tan Khat; Dong Van Le; Kiet Dinh Truong; Ngoc Kim Phan
Journal:  Onco Targets Ther       Date:  2012-05-07       Impact factor: 4.147

6.  Immunodetection of cells with a CD44+/CD24- phenotype in canine mammary neoplasms.

Authors:  Geórgia Modé Magalhães; Erika Maria Terra; Rosemeri de Oliveira Vasconcelos; Márcio de Barros Bandarra; Pamela Rodrigues Reina Moreira; Mayara Caroline Rosolem; Antonio Carlos Alessi
Journal:  BMC Vet Res       Date:  2013-10-11       Impact factor: 2.741

7.  Expression of Tumor-Related Macrophages and Cytokines After Surgery of Triple-Negative Breast Cancer Patients and its Implications.

Authors:  Jianguo Wang; Hongwu Chen; Xingwu Chen; Hui Lin
Journal:  Med Sci Monit       Date:  2016-01-11

8.  Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype.

Authors:  W A da Silveira; P V B Palma; R D Sicchieri; R A R Villacis; L R M Mandarano; T M G Oliveira; H M R Antonio; J M Andrade; V F Muglia; S R Rogatto; C Theillet; S du Manoir; D G Tiezzi
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

9.  Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.

Authors:  Polina Weitzenfeld; Tsipi Meshel; Adit Ben-Baruch
Journal:  Oncotarget       Date:  2016-12-06

10.  Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer.

Authors:  Katerina D Fagan-Solis; Denise K Reaves; M Cristina Rangel; Michel R Popoff; Bradley G Stiles; Jodie M Fleming
Journal:  Mol Cancer       Date:  2014-07-02       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.